Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
P&G licenses GI product
July 17, 2006
| A version of this story appeared in
Volume 84, Issue 29
Procter & Gamble Pharmaceuticals will develop and commercialize ARYx's ATI-7505, currently in Phase II trials for the treatment of gastrointestinal disorders. P&G will pay $25 million up front; milestone and royalty payments could bring the value of the deal to $435 million. ATI-7505, an oral serotonin type 4 agonist, is in the same class of drugs as Propulsid, which was withdrawn because of safety issues after raking in almost $1 billion in sales. ARYx says it engineered ATI-7505 to work by the same mechanism as Propulsid, but without the negative side effects. Manufacturing of ATI-7505 was outsourced earlier to Ultrafine, now part of Sigma-Aldrich's SAFC unit.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter